No headlines found.
No press releases found.
No news found.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
Seaport Therapeutics trades on the NASDAQ stock market under the symbol SPTX.
As of May 13, 2026, SPTX stock price climbed to $16.50 with 430,589 million shares trading.
SPTX has a market cap of $874.96 million. This is considered a Small Cap stock.
SPTX support price is $14.91 and resistance is $16.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPTX shares will trade within this expected range on the day.
